LILRB1
Leukocyte immunoglobulin-like receptor subfamily B member 1
Also known as: LIRB1_HUMAN
Protein identityUniProt · HPA
- UniProt accession
- Q8NHL6
- Gene
- LILRB1
- Canonical length
- 650 aa
- Protein class
- Predicted membrane proteins
OverviewNCBI Gene
No narrative summary is available for LILRB1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
650 residues, UniProt reviewed canonical sequence.
>Q8NHL6|LILRB1
1 MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ GGQETQEYRL
61 YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY GSDTAGRSES SDPLELVVTG
121 AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA FDGFSLCKEG EDEHPQCLNS QPHARGSSRA
181 IFSVGPVSPS RRWWYRCYAY DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE
241 TLTLQCGSDA GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA
301 HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG WMQTFLLTKE
361 GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS QSSKPYLLTH PSDPLELVVS
421 GPSGGPSSPT TGPTSTSGPE DQPLTPTGSD PQSGLGRHLG VVIGILVAVI LLLLLLLLLF
481 LILRHRRQGK HWTSTQRKAD FQHPAGAVGP EPTDRGLQWR SSPAADAQEE NLYAAVKHTQ
541 PEDGVEMDTR SPHDEDPQAV TYAEVKHSRP RREMASPPSP LSGEFLDTKD RQAEEDRQMD
601 TEAAASEAPQ DVTYAQLHSL TLRREATEPP PSQEGPSPAV PSIYATLAIHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LILRB1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 48 nTPM
Expression across tissuesHPA
Tissue
- spleen: 48 nTPM
- appendix: 23 nTPM
- lymph node: 9.9 nTPM
- lung: 8.9 nTPM
- small intestine: 7.1 nTPM
- bone marrow: 6.7 nTPM
Single-cell type
- microglia: 73 nCPM
- monocytes: 22 nCPM
- macrophages: 7.4 nCPM
- b-cells: 6.8 nCPM
- pdcs: 5.2 nCPM
- nk-cells: 3.7 nCPM
Immune cell
- non-classical monocyte: 74 nTPM
- intermediate monocyte: 53 nTPM
- classical monocyte: 12 nTPM
- myeloid DC: 6.8 nTPM
- plasmacytoid DC: 6.8 nTPM
- total PBMC: 6.6 nTPM
Brain region
- white matter: 5.6 nTPM
- medulla oblongata: 3.9 nTPM
- spinal cord: 3.4 nTPM
- pons: 3.3 nTPM
- thalamus: 2.9 nTPM
- midbrain: 2.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.06
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.91
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- cellular response to lipopolysaccharide
- defense response to virus
- dendritic cell differentiation
- Fc receptor mediated inhibitory signaling pathway
- immune response-inhibiting cell surface receptor signaling pathway
- immune response-regulating signaling pathway
- interleukin-10-mediated signaling pathway
- negative regulation of alpha-beta T cell activation
- negative regulation of calcium ion transport
- negative regulation of CD8-positive, alpha-beta T cell activation
- negative regulation of cell cycle
- negative regulation of cytokine production involved in immune response
- negative regulation of dendritic cell apoptotic process
- negative regulation of dendritic cell differentiation
- negative regulation of endocytosis
- negative regulation of interferon-beta production
- negative regulation of interleukin-10 production
- negative regulation of interleukin-12 production
- negative regulation of mononuclear cell proliferation
- negative regulation of natural killer cell mediated cytotoxicity
- negative regulation of osteoclast development
- negative regulation of serotonin secretion
- negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
- negative regulation of T cell mediated cytotoxicity
- negative regulation of T cell proliferation
- negative regulation of transforming growth factor beta production
- negative regulation of tumor necrosis factor production
- negative regulation of type II interferon production
- positive regulation of apoptotic process
- positive regulation of defense response to virus by host
- positive regulation of gene expression
- positive regulation of macrophage cytokine production
- positive regulation of transcription by RNA polymerase II
- positive regulation of type II interferon production
- receptor internalization
- response to virus
- signal transduction
- T cell proliferation involved in immune response
- positive regulation of gamma-delta T cell activation involved in immune response
Molecular functions
- HLA-B specific inhibitory MHC class I receptor activity
- inhibitory MHC class I receptor activity
- MHC class I protein binding
- MHC class I receptor activity
- MHC class Ib protein binding
- MHC class Ib protein complex binding
- MHC class Ib receptor activity
- protein homodimerization activity
- protein phosphatase 1 binding
- SH2 domain binding
- HLA-A specific inhibitory MHC class I receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LILRB1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LILRB1 as an antibody target. Whether an autoantibody or antibody against LILRB1 could matter depends on whether native LILRB1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LILRB1 is annotated at the cell surface, where native LILRB1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LILRB1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...